Gene expression profiling in non-Hodgkin lymphomas.

摘要: Although the current WHO classification (Swerdlow et al. of tumours haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, 2008 [1]) hematolymphoid neoplasms has delineated lymphomas based combined morphologic, immunophenotypic, genotypic findings, further refinement is necessary especially in regard to therapeutics prognostic implications. High-throughput gene expression profiling (GEP) using microarray technology (Schena Science 270:467–470, 1995 [2]; Augenlicht Proc Natl Acad Sci USA 88:3286-3289, 1991 [3]) was developed about 20 years ago, analytical approaches enabled us routinely evaluate practically entire transcriptome at a time. GEP helped improve prognostication non-Hodgkin (NHL) as well improved our understanding their pathophysiology response new therapeutics. In this paper, we will briefly review how revolutionary tool transformed given insight into targeted We also discuss efforts adapting findings routine clinical practice, evolution research directions future.